This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?
by Zacks Equity Research
Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.
What's in Store for Varian Medical (VAR) in Q1 Earnings?
by Zacks Equity Research
Demand for Eclipse and TrueBeam is expected to have driven Varian's (VAR) Oncology revenues in fiscal Q1.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.
Here's Why You Should Add DexCom (DXCM) to Your Portfolio
by Zacks Equity Research
DexCom (DXCM) expects its strong product portfolio to consistently drive top line.
Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now
by Zacks Equity Research
Veeva (VEEV) sees a slew of positive developments.
Here's Why DexCom (DXCM) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Diabetes Management Gains FDA Attention: 3 Stocks in Focus
by Sriparna Ghosal
The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.
Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results
by Zacks Equity Research
Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.
Allscripts Expands Partnership With PIH Health Through 2025
by Zacks Equity Research
Encouraged by its solid EHR prospects, Allscripts (MDRX) expects a surge in its fourth-quarter 2019 bookings.
Inogen (INGN) Announces Preliminary Q4 Results, Slashes View
by Zacks Equity Research
Inogen (INGN) expects direct-to-consumer sales to be its fastest-growing channel in 2020.
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $235.06, moving -0.33% from the previous trading session.
ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View
by Zacks Equity Research
ABIOMED's (ABMD) Q3 international revenues grew year over year; fiscal 2020 view slashed.
Here's Why You Should Add Cerner (CERN) to Your Portfolio
by Zacks Equity Research
Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion in the fourth quarter.
Here's Why You Should Hold on to AngioDynamics Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $233.23 in the latest trading session, marking a +0.77% move from the prior day.
Walgreens Boots (WBA) Q1 Earnings Lag Estimates, Margins Fall
by Zacks Equity Research
Sluggishness in Walgreens Boots' (WBA) Retail Pharmacy International segment and margin contractions put pressure on the bottom line during Q1.
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AngioDynamics (ANGO) Q2 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.
Here's Why You Should Hold on to Becton, Dickinson Stock Now
by Zacks Equity Research
Becton, Dickinson (BDX) expects fiscal 2020 revenue growth to be driven by recent product launches.
Top-Ranked ETFs, Stocks From Top Sector of the Last Decade
by Sweta Killa
Amid a plethora of challenges, Wall Street was on a spectacular run over the last decade, rising from the depths of the financial crisis and Great Recession.
Here's Why You Should Hold on to Intuitive Surgical for Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction remains a concern.
Here's Why You Should Invest in Patterson Companies Stock Now
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.